VISTA PHARMACEUTICALS LTD. (VISTAPH) fair value: what the stock is really worth
As of Nov 19, 2026: fair value (intrinsic value) of VISTA PHARMACEUTICALS LTD. stock ₹5.65, price ₹6.15, that is 8.1% below the price, quality 24 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
VISTA PHARMACEUTICALS LTD.
VISTAPH · BSEThe stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range ₹5.36 – ₹19.32 · fair‑value band ₹4.24 – ₹7.07 · the ₹6.15 price screens above the ₹5.65 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether VISTA PHARMACEUTICALS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Vista Pharmaceuticals Limited manufactures and sells pharmaceutical, medical, and veterinary preparations in India, the United States, and internationally. It offers over the counter and prescription generic drugs consisting of tablets, capsules, and liquids covering various therapeutic categories.
Show moreShow less
Vista Pharmaceuticals Limited was incorporated in 1991 and is based in Hyderabad, India.
Stock analysis
VISTA PHARMACEUTICALS LTD. (VISTAPH) currently trades at ₹6.15, while our estimate is ₹5.65, so the stock looks roughly fairly valued today (gap 8.8%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: ₹4.24 (bear) to ₹7.07 (bull), the price of ₹6.15 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
VISTA PHARMACEUTICALS LTD. reported revenue of ₹54.0M in FY2026 versus ₹3.9M in FY2022, a compound +92.3%/yr. Reported net income was −₹121M in FY2026.
Key figures
Market cap ₹379M (≈ $4.1M) Micro · P/S ratio 4.60 · EPS (TTM) ₹−1.92 · Return on equity −16.6% · Return on assets (EBIT) −10.5% (5-year average) · Operating margin −2,584% · Revenue (TTM) ₹86.3M · Revenue growth (YoY) −97.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −8%, VISTAPH screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Watch VISTAPH, get fair value alerts →
Compare VISTA PHARMACEUTICALS LTD. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Fair value gap by industry
- Return on assets by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $85.57 | $113.53 | +33% | vs VISTAPH |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥46.88 | ¥52.43 | +12% | vs VISTAPH |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,900 | ₹1,983 | +4% | vs VISTAPH |
| Haleon plc HLN | $9.08 | $8.47 | −7% | vs VISTAPH |
| Merck KGaA MRK | €148.40 | €108.83 | −27% | vs VISTAPH |
| Galderma Group GALD | CHF 184.70 | CHF 112.46 | −39% | vs VISTAPH |
| Takeda Pharmaceutical Company TAK | $21.27 | $11.23 | −47% | vs VISTAPH |
| Sandoz Group SDZ | CHF 81.24 | CHF 41.06 | −49% | vs VISTAPH |
| Teva Pharmaceutical Industries Limited TEVA | $42.23 | $20.74 | −51% | vs VISTAPH |
| Divi's Laboratories Limited DIVISLAB | ₹11,178 | ₹1,567 | −86% | vs VISTAPH |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is VISTA PHARMACEUTICALS LTD. (VISTAPH) overvalued or undervalued?
What is the fair value of VISTAPH?
What is the quality score of VISTAPH?
What is the price target for VISTA PHARMACEUTICALS LTD. (VISTAPH)?
What is the VISTA PHARMACEUTICALS LTD. stock forecast for 2026?
What is the revenue of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
What is the intrinsic value of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
Is VISTA PHARMACEUTICALS LTD. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of VISTAPH?
How much is VISTA PHARMACEUTICALS LTD. worth?
What do the bullish and bearish scenarios say about VISTAPH?
How solid is the balance sheet of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
How far is VISTAPH from its 52-week high?
Which stocks are comparable to VISTA PHARMACEUTICALS LTD.?
Is VISTA PHARMACEUTICALS LTD. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
What should I pay attention to with VISTA PHARMACEUTICALS LTD. right now?
Key figures of VISTA PHARMACEUTICALS LTD.
How large is the market capitalisation of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
What is the P/S ratio of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
What are the earnings per share of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
What is the return on equity of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
What is the EBIT return on assets of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
What is the operating margin of VISTA PHARMACEUTICALS LTD. (VISTAPH)?
How fast is revenue growing at VISTA PHARMACEUTICALS LTD. (VISTAPH)?
How much free cash flow does VISTA PHARMACEUTICALS LTD. (VISTAPH) generate?
How much net debt does VISTA PHARMACEUTICALS LTD. (VISTAPH) carry?
Watch VISTA PHARMACEUTICALS LTD. in the live analysis
One click puts VISTA PHARMACEUTICALS LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.